viewKazia Therapeutics Ltd

Kazia Therapeutics to present positive ovarian cancer drug data at AACR annual meeting

Kazia Therapeutics Ltd (NASDAQ:KZIA) (ASX:KZA) chief executive officer James Garner speaks to Proactive Investors about the oncology-focused biotech’s ongoing phase-one study of its Cantraxil treatment for ovarian cancer.

Positive summarising data from the study will be presented today at the American Association of Cancer Research annual meeting in Atlanta, GA.

“We’ve had some really good feedback actually … one of the things that’s been exciting is that in addition to the safety data we’ve presented, there’s some pointers that our drug is working,” Garner says.

He continues, “We saw more than half of the patients, actually what we call stable disease, that suggest that the drug is slowly or stopping the progression of their cancer.”

Quick facts: Kazia Therapeutics Ltd

Price: 0.93 AUD

Market: ASX
Market Cap: $67.12 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Kazia Therapeutics Ltd named herein, including the promotion by the Company of Kazia Therapeutics Ltd in any Content on the Site, the Company...


Kazia Therapeutics CEO hails Fast Track Designation for Paxalisib

Kazia Therapeutics Ltd's (ASX:KZA) (NASDAQ:KZIA) Dr James Garner caught up with Proactive's Andrew Scott following the news it's been awarded US Food and Drug Administration (FDA) Fast Track Designation (FTD) for Paxalisib for the treatment of glioblastoma – the most common and aggressive form...

on 08/21/2020

2 min read